ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Ublituximab (Primary) ; Teriflunomide
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ULTIMATE II
- Sponsors TG Therapeutics Inc
- 15 Sep 2017 According to a TG Therapeutics media release, global ULTIMATE I and II trials are being led by Dr. Lawrence Steinman.
- 07 Sep 2017 Status changed from planning to recruiting.
- 03 Aug 2017 New trial record